Effect and Safety of Mycophenolate Mofetil or Sodium in Systemic Sclerosis-Associated Interstitial Lung Disease: A Meta-Analysis
Background. Interstitial lung disease (ILD) is the most common complication of systemic sclerosis (SSc) with treatment ineffective. Objective: The aim of this meta-analysis was to provide an estimate of the safety and efficacy profile of Mycophenolate Mofetil (MMF) or sodium (MMS) in SSc-ILD patient...
Saved in:
Main Authors: | Argyris Tzouvelekis, Nikolaos Galanopoulos, Evangelos Bouros, George Kolios, George Zacharis, Paschalis Ntolios, Andreas Koulelidis, Anastasia Oikonomou, Demosthenes Bouros |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2012-01-01
|
Series: | Pulmonary Medicine |
Online Access: | http://dx.doi.org/10.1155/2012/143637 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Effect and Safety of Mycophenolate Mofetil in Idiopathic Pulmonary Fibrosis
by: Argyris Tzouvelekis, et al.
Published: (2011-01-01) -
Mycophenolate Mofetil and Clostridium difficile-associated Colitis
by: A. I. Dolgushina, et al.
Published: (2021-12-01) -
Cyclophosphamide and mycophenolate mofetil as induction therapy in lupus nephritis
by: Božić-Majstorović Ljubinka, et al.
Published: (2024-01-01) -
Mycophenolate mofetil induced transfusion dependent anemia in lupus
by: Anand Prahalad Rao, et al.
Published: (2018-01-01) -
Mycophenolate Mofetil for the Treatment of Autoimmune Hepatitis in Patients Refractory to Standard Therapy
by: Shane M Devlin, et al.
Published: (2004-01-01)